Queens
Long Island City (LIC)
30-07 36th Ave, Long Island City, NY 11106
A western Queens access point for patients balancing treatment days with work, home, or Manhattan commutes.
View location detailsSpravato near you
Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant.
SPRAVATO care requires repeated monitored visits. Ask about a convenient clinic, care-manager support and scheduling, and confirm coverage for the clinician and treatment under your exact insurance plan.
No. Ask which costs cover the Spravato medicine, supervised administration, monitoring, psychiatric assessment and continuing reviews. Transport can create a separate practical expense. Confirm the benefit route, approved treatment dates, session limits, pharmacy and patient responsibility. Manufacturer assistance has eligibility rules and does not establish the total clinic charge. A payer approving one dose or course does not guarantee a renewal or payment of every claim. Request the proposed costs before the session and clarify changes in coverage, deductibles or authorized frequency.
Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behaviour; that use requires an oral antidepressant. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behaviour, and it does not replace hospitalization when that is needed.
Assessment reviews the diagnosis, previous treatments and whether they were taken at an adequate dose and duration. The clinician checks blood pressure, cardiovascular and cerebrovascular history, psychosis, substance-use risks, pregnancy and interacting medicines. Aneurysmal vascular disease, arteriovenous malformation, a history of intracerebral hemorrhage and hypersensitivity are labelled contraindications. Insurer criteria can differ from the clinical label.
Bring antidepressant names, doses, dates, response, adverse effects and relevant hospital records. Clarify whether the proposed treatment is TRD care or the separate acute suicidal MDD indication. Discuss other suitable treatments and continuing therapy.
Spravato is administered through its REMS in a certified healthcare setting. Patients self-administer the nasal spray under direct supervision. Blood pressure is checked before dosing, around 40 minutes afterwards and further as needed. Breathing is monitored, including pulse oximetry, for at least two hours. Release occurs only when the clinician finds the patient stable. Some visits take longer.
TRD treatment is twice weekly for the first four weeks, then weekly in weeks five through eight. From week nine, dosing is weekly or every two weeks according to response. The clinician assesses benefit after the initial four weeks. The acute suicidal MDD regimen is a separate twice-weekly four-week course. Longer use for that indication has not been systematically evaluated.
Arrange transport home and leave time for the observation period. Do not eat for at least two hours before a dose or drink liquids for at least 30 minutes before it. If using a nasal corticosteroid or decongestant, follow the label’s timing of at least one hour before Spravato. Bring the medicine list and report alcohol, sedatives, opioids or new symptoms. Do not change other medicines without instructions.
The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours associated with antidepressants in younger people. Do not drive, operate machinery or undertake activities requiring full alertness until the next day after a restful sleep. Arrange a ride home even if you feel ready to drive. Blood-pressure elevation can make a session unsuitable. Spravato may harm the fetus during pregnancy and breastfeeding is not recommended during treatment. Urgent worsening depression or a suicide crisis needs immediate clinical or emergency care rather than waiting for the next session.
Track depression symptoms, daily function, adverse effects and missed sessions with the treating team. A late session is not a reason to double a dose. If maintenance sessions are missed and symptoms worsen, the clinician may consider returning to a previous frequency. Continuing care includes psychiatric review and safety planning, not just attendance at nasal-spray visits.
Ask for separate confirmation of medication coverage, administration and monitoring charges, authorization dates and the number of approved visits. A previous approval does not guarantee a new dose, renewal or paid claim. Ask about appeals and documentation if denied. Confirm the selected site’s REMS status, appointment capacity and transport policy directly. Ask whether the medicine is ready and which charges are approved.
Choose a treatment site that fits your prescribed visits and transport needs. Spravato must be taken under supervision in an enrolled REMS setting with at least two hours of monitoring. Arrange a ride home and do not drive until the next day after a restful sleep. Intake can help identify the actual dosing location and appointment.
Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.
Ask the exact plan whether nonemergency transport is a benefit, which service arranges it and whether an escort is required. A treatment approval does not establish transport approval. For a sedating treatment, arrange a safe ride before dosing. Do not rely on an unconfirmed benefit or drive yourself.
Choose a confirmed REMS-certified service that can support the prescribed schedule, monitoring and a safe trip home. Ask which exact sites are actively dosing, available appointment times, medication access, plan acceptance and psychiatric responsibility. A nearby location or regional listing does not establish an active Spravato session.
No. Follow the label’s restriction until the next day after a restful sleep. Arrange transport home. Two hours is a minimum observation period, not driving clearance.
No such general claim is supported. The current TRD regimen uses 56 mg or 84 mg according to the prescribed plan and tolerability. Insurer authorization and clinical dose selection are separate decisions.
Contact the clinic and insurer promptly to check authorization dates, approved services and claim reasons before assuming future sessions are covered. Ask for the clinical documentation and appeal process. Prior treatment alone does not establish continued payment.
Ask the treating clinician for your written schedule. Confirm the selected clinic can accommodate the prescribed visits before making travel or work arrangements.
Treatment-resistant depression generally describes depression that has not responded adequately to at least two antidepressants tried at an adequate dose and duration. A clinician must review the diagnosis and treatment history.
Nao Medical’s confirmed Spravato service locations are Long Island City (LIC), Mineola, Long Island, Williamsburg, Brooklyn, Manhattan, NYC, Bartow, Bronx, Hicksville, Long Island, Jamaica, Queens, Astoria, Queens, Crown Heights, Brooklyn. Confirm the appointment and plan requirements with the selected service.
Queens
30-07 36th Ave, Long Island City, NY 11106
A western Queens access point for patients balancing treatment days with work, home, or Manhattan commutes.
View location detailsLong Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for patients who want strong benefits support and reliable treatment coordination.
View location detailsBrooklyn
308 Graham Ave, Brooklyn, NY 11211
The lead Brooklyn Spravato location for patients who want local access and ongoing psychiatric support.
View location detailsManhattan
259 1st Ave, New York, NY 10003
A Manhattan Spravato access point for East Village, Gramercy, Kips Bay, and nearby neighborhoods.
View location detailsBronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for patients who want local Spravato care without leaving the borough.
View location detailsLong Island
232 W Old Country Rd, Hicksville, NY 11801
A central Nassau option for patients who need consistent follow-up, prior auth support, and a shorter commute.
View location detailsQueens
90-18 Sutphin Blvd, Jamaica, NY 11435
A southeast Queens location that helps patients stay on schedule for repeated monitored sessions.
View location detailsQueens
37-15 23rd Ave, Astoria, NY 11105
A western Queens option for patients who want easier access than crossing into Manhattan for every monitored treatment day.
View location details341 Eastern Pkwy, Brooklyn, NY 11216
Confirm evaluation and treatment appointments with the service.
Call the clinic: (917) 310-3371These nine Nao Medical locations provide Spravato services. Confirm evaluation and treatment appointments, medication arrangements and plan requirements with your selected service.